下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEUNBS5162Cat. No.: HY-16509CAS No.: 956590-23-1分式: CHNO分量: 326.35作靶點(diǎn): CXCR; Autophagy作通路: GPCR/G Protein; Immunology/Inflammation; Autophagy儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 21
2、.5 mg/mL (65.88 mM; Need ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 3.0642 mL 15.3210 mL 30.6419 mL5 mM 0.6128 mL 3.0642 mL 6.1284 mL10 mM 0.3064 mL 1.5321 mL 3.0642 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 UNBS5162種譜的趨化因配體 CXCL 拮抗劑,具有抗腫瘤活性。
3、IC50 & Target CXCL體外研究UNBS5162 is a pan-antagonist of CXCL chemokine expression and exhibits weak antiproliferative activityagainst human cancer cell lines with mean IC50 of 17.9 M. UNBS5162 markedly impairs PC-3 tumor cellgrowth kinetics, without inducing senescence, whereas the reverse feature is
4、observed with respect to DU-1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE145 cells 1. UNBS5162 is cytotoxic to a range of human cancer cell lines including glioblastoma (Hs683 andU373MG), colorectal (HCT-15 and LoVo), non-small-cell lung (A549) and breast (MCF-7), with IC50s of 0.5-5M. UNBS5162
5、also markedly increases the levels of expression of LC3-I and LC3-II in human cancer cells.UNBS5162 displays no anti-topoisomerase II activity. Moreover, UNBS5162 induces cancer cell deaththrough lysosomal membrane permeabilization (LMP) in PC3 prostate cancer cells but not in U373glioblastoma cells
6、, with this LMP process occurring as an UNBS5162-induced decrease in Hsp70 expression2. UNBS5162 inhibits the proliferation of esophageal cancer squamous cells via the PI3K/AKT signalingpathway. UNBS5162 downregulates the protein expression of proteins associated with the PI3K/AKTsignaling pathway,
7、including the levels of phosphorylated (p)-AKT, p-mechanistic target of rapamycin kinase,ribosomal protein S6 kinase 1 and cyclin D1 3.體內(nèi)研究 UNBS5162 (20 mg/kg, i.v.) increases the therapeutic benefits of taxol in vivo in the orthotopic human PC-3prostate cancer model 1.PROTOCOLAnimal Mice 1Administr
8、ation 1 Orthotopic xenografts are obtained by injecting 2.5 106 human PC-3 or DU-145 cells into the prostate of 6-week-old male nu/nu mice (n = 9 animals per treatment group). All grafts are performed under anesthesiasaline/Rompun/Imalgene; 5:1:1 by volume. The end point in these orthotopic experime
9、nts is the survivalperiod of the tumor-bearing mice after the administration of UNBS3157, UNBS5162, or reference anticanceragents (taxol, mitoxantrone, and amonafide). However, for ethical reasons, animals are killed when 20% ofbody weight have been lost compared to that determined at the time of tu
10、mor grafting. All animals areweighed three times a week. Autopsies and histologic diagnoses are performed on each mouse to confirmthe presence of tumor development; 100% is achieved. In the case of UNBS5162 experiments in the PC-3model, after the sacrifice of animals, tumors are removed from both dr
11、ug-treated 10 mg/kg, intravenous(i.v.) and vehicle-treated mice, fixed in buffered formalin, embedded in paraffin, and 5-m-thick sectionstaken. These histologic slides are then stained with hematoxylin and eosin for blood vessel counts 1.MCE has not independently confirmed the accuracy of these meth
12、ods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Onco Targets Ther. 2017 Nov 6;10:5303-5309. Thorac Cancer. 2018 Jan;9(1):105-111. Drug Dev Ind Pharm. 2019 Apr 17:1-17. Cancer Manag Res. 2019 Mar 22;11:2339-2348. Mol Med Rep. 2018 Jan;17(1):549-555.See more customer validations on HYPERLINK / www.MedChe
13、mEREFERENCES2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE1. Mijatovic T, et al. UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.Neoplasia. 2008 Jun;10(6):573-86.2. Tina Mahieu, et al. UNBS5162: A novel naphthalimide derivative with potent pro-autophagic effects in human cancer cells. CancerResearch, 2007 May; 67(9) Supplement.3. He D, et al. UNBS5162 inhibits the proliferation of esophageal cancer squamous cells via the PI3K/AKT signaling pathway. Mol MedRep. 2018 Jan;17(1):54
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年度數(shù)據(jù)中心運(yùn)營(yíng)維護(hù)承包人工合同模板4篇
- 2025年度互聯(lián)網(wǎng)數(shù)據(jù)中心搭建服務(wù)合同協(xié)議3篇
- 2025年度化工原料采購與儲(chǔ)存協(xié)議3篇
- 2025年度環(huán)保型綠色打印設(shè)備承包合同范本3篇
- 2025年度汽車4S店集團(tuán)購車優(yōu)惠及售后服務(wù)協(xié)議3篇
- 2024衣柜墻板吊頂裝修工程施工安全與環(huán)境保護(hù)合同
- 創(chuàng)新集成電路設(shè)計(jì)與制造技術(shù)項(xiàng)目可行性研究報(bào)告范文模板
- 《融資租賃行業(yè)培訓(xùn)》課件
- 2025年度房產(chǎn)中介服務(wù)傭金結(jié)算標(biāo)準(zhǔn)合同4篇
- 2025年度別墅裝修工程承包與監(jiān)理協(xié)議4篇
- 二零二五年度數(shù)據(jù)存儲(chǔ)與備份外包服務(wù)協(xié)議2篇
- 家政服務(wù)與社區(qū)合作方案
- 2024年深圳市龍崗區(qū)城市建設(shè)投資集團(tuán)有限公司招聘筆試真題
- 2024-2025學(xué)年北京市朝陽區(qū)高三上學(xué)期期末考試數(shù)學(xué)試卷(含答案)
- 第五單元《習(xí)作例文:風(fēng)向袋的制作》說課稿-2024-2025學(xué)年五年級(jí)上冊(cè)語文統(tǒng)編版
- 四年級(jí)數(shù)學(xué)(除數(shù)是兩位數(shù))計(jì)算題專項(xiàng)練習(xí)及答案
- 四川省綿陽市涪城區(qū)2024-2025學(xué)年九年級(jí)上學(xué)期1月期末歷史試卷(含答案)
- 2025年山東水發(fā)集團(tuán)限公司社會(huì)招聘高頻重點(diǎn)提升(共500題)附帶答案詳解
- JJG 1204-2025電子計(jì)價(jià)秤檢定規(guī)程(試行)
- 2024年計(jì)算機(jī)二級(jí)WPS考試題庫(共380題含答案)
- 《湖南省房屋建筑和市政工程消防質(zhì)量控制技術(shù)標(biāo)準(zhǔn)》
評(píng)論
0/150
提交評(píng)論